I-Mab (NASDAQ:NBP) Posts Quarterly Earnings Results

I-Mab (NASDAQ:NBP) posted its quarterly earnings results on Thursday. The company reported ($0.16) EPS for the quarter, FiscalAI reports.

I-Mab Trading Down 3.5%

NBP opened at $1.91 on Friday. I-Mab has a 52 week low of $1.46 and a 52 week high of $6.79. The stock has a market cap of $220.89 million, a PE ratio of -5.31 and a beta of 1.47. The company has a 50 day moving average price of $1.77.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of I-Mab in a research report on Thursday. Weiss Ratings upgraded shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, I-Mab has an average rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group purchased a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors and hedge funds.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.